Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs PayPal Holdings, Inc. (PYPL) Price & Performance

Cassava Sciences IncTrade
PayPal Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs PayPal Holdings, Inc. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while PayPal Holdings, Inc. trades at $58.91 (market cap $50.53B). The key difference: PayPal Holdings, Inc. is far larger — about 1058.2× Cassava Sciences Inc's market cap, and PayPal Holdings, Inc. pays a 0.95% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAPYPL
Market Cap
$47.75M$50.53B
Sector
HealthFinancials
52-Week High
$4.64$76.13
52-Week Low
$0.87$39.08
Enterprise Value
-$34.93M$52.68B
Dividend Yield
0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

PayPal Holdings, Inc.

PayPal (PYPL) trades at $59.07, down 1.19% on the day, with a bullish technical outlook supported by moving averages and strong cash flow. Recent earnings beat expectations, with Q2 2026 EPS of $1.38 exceeding the $1.28 consensus, while revenue grew 4.8% year-over-year. The company raised full-year 2026 guidance, signaling confidence in its turnaround under new leadership, amid acquisition interest from Stripe and Advent International at a $53 billion valuation rejected by the board.

PYPL presents a value opportunity with a low P/E of 11.17 and robust free cash flow, but faces risks from competitive pressures and economic sensitivity. Analyst consensus is mixed with 35.7% buy ratings, though institutional buying and undervaluation narratives support upside potential if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About PayPal Holdings, Inc.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.

Read more on PYPL